Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Background Androgen deprivation therapy (ADT) is foundational in the management of
advanced prostate cancer (PCa) and has benefitted from a recent explosion in scientific …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

PURPOSE Update all preceding ASCO guidelines on initial hormonal management of
noncastrate advanced, recurrent, or metastatic prostate cancer. METHODS The Expert …

Metastatic prostate cancer patients present in two ways—with already disseminated disease
at the time of presentation or with disease recurrence after definitive local therapy. Androgen …

Androgen deprivation therapy (ADT) has been the main management strategy for prostate
cancer for more than eight decades, nowadays achieved commonly by administration of …

The advent of more effective treatment combinations for metastatic hormone-sensitive
prostate cancer (mHSPC) has been built on successes in therapy development for …

Prostate cancer (PC) is a common and widespread cancer that affects men globally. A
complicated interaction of hormonal variables influences its development. Sex hormone …

Prostate cancer (PC) is one of the common malignant tumors of the male genitourinary
system. Here, we constructed PTX@ ZIF-8, which is a metal-organic-framework …